Efficacy Summary (CAM211)
Campath was effective in patients with CLL who had failed fludarabine
- Objective response rate - 33.3% (95% CI [24, 44])
- Survival - 16 months (95% CI [11.8, --])
Measurable clinical benefits
Supportive studies consistent
(125-005 and 125-009 Studies)